UK approves first oral GLP‑1 weight‑loss pill, prompting massive consumer interest

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized oral semaglutide, marketed as the first tablet GLP‑1 treatment for weight management in the United Kingdom. The new pill, dubbed oral Wegovy, is expected to be available in pharmacies within weeks. Within 24 hours of the announcement more than 70,000 people registered interest, with Pharmacy Simple seeing over 60,000 sign‑ups and Superdrug reporting a 130 % surge. Waiting lists at private pharmacies now exceed 10,000 customers.

The tablet is priced at roughly £99 per month (£3 per day) and will be offered via private prescription; NHS coverage will require approval from the National Institute for Health and Care Excellence (NICE). Clinical data show an average weight loss of just under 14 % of body weight over 64 weeks, comparable to injectable GLP‑1 products. Surveys indicate that 61 % of people not using GLP‑1 drugs would prefer a daily pill to weekly injections. While clinicians welcome the non‑injectable option, they caution that treatment remains limited to patients meeting specific clinical criteria and stress the importance of focusing on health outcomes rather than aesthetic goals.